vs
Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). On growth, ACV Auctions Inc. posted the faster year-over-year revenue change (15.1% vs 5.0%). Over the past eight quarters, ACV Auctions Inc.'s revenue compounded faster (12.3% CAGR vs -0.2%).
ACV Auctions Inc.ACVAEarnings & Financial Report
ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ACVA vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.6M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -9.7% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 15.1% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.12 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $183.6M | $196.9M | ||
| Q3 25 | $199.6M | $179.5M | ||
| Q2 25 | $193.7M | $181.1M | ||
| Q1 25 | $182.7M | $168.9M | ||
| Q4 24 | $159.5M | $187.3M | ||
| Q3 24 | $171.3M | $168.6M | ||
| Q2 24 | $160.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-24.5M | $5.4M | ||
| Q2 25 | $-7.3M | $-4.8M | ||
| Q1 25 | $-14.8M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-16.0M | $-143.5M | ||
| Q2 24 | $-17.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -9.7% | 1.2% | ||
| Q3 25 | -11.9% | 3.5% | ||
| Q2 25 | -3.7% | 4.7% | ||
| Q1 25 | -7.9% | 1.2% | ||
| Q4 24 | -16.2% | 13.2% | ||
| Q3 24 | -10.0% | -82.8% | ||
| Q2 24 | -11.6% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -12.3% | 3.0% | ||
| Q2 25 | -3.8% | -2.7% | ||
| Q1 25 | -8.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -9.4% | -85.1% | ||
| Q2 24 | -10.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.12 | $0.05 | ||
| Q3 25 | $-0.14 | $0.12 | ||
| Q2 25 | $-0.04 | $-0.11 | ||
| Q1 25 | $-0.09 | $0.10 | ||
| Q4 24 | $-0.15 | $0.38 | ||
| Q3 24 | $-0.10 | $-3.11 | ||
| Q2 24 | $-0.10 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.5M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $429.7M | $653.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $271.5M | $238.4M | ||
| Q3 25 | $265.3M | $246.3M | ||
| Q2 25 | $258.4M | $445.9M | ||
| Q1 25 | $291.9M | $493.6M | ||
| Q4 24 | $224.1M | $484.6M | ||
| Q3 24 | $252.5M | $453.8M | ||
| Q2 24 | $215.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $429.7M | $693.1M | ||
| Q3 25 | $434.4M | $727.2M | ||
| Q2 25 | $448.8M | $757.8M | ||
| Q1 25 | $439.6M | $798.5M | ||
| Q4 24 | $440.0M | $778.3M | ||
| Q3 24 | $456.2M | $749.6M | ||
| Q2 24 | $457.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $984.1M | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.4M | — |
| Free Cash FlowOCF − Capex | $-14.7M | — |
| FCF MarginFCF / Revenue | -8.0% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $69.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-12.4M | $43.7M | ||
| Q3 25 | $10.3M | $60.8M | ||
| Q2 25 | $13.7M | $12.0M | ||
| Q1 25 | $66.6M | $35.5M | ||
| Q4 24 | $-3.2M | $33.1M | ||
| Q3 24 | $21.1M | $53.9M | ||
| Q2 24 | $4.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-14.7M | $43.5M | ||
| Q3 25 | $7.7M | $57.0M | ||
| Q2 25 | $10.9M | $9.3M | ||
| Q1 25 | $65.3M | $26.9M | ||
| Q4 24 | $-3.9M | $31.0M | ||
| Q3 24 | $20.2M | $49.8M | ||
| Q2 24 | $2.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -8.0% | 22.1% | ||
| Q3 25 | 3.8% | 31.7% | ||
| Q2 25 | 5.6% | 5.1% | ||
| Q1 25 | 35.7% | 15.9% | ||
| Q4 24 | -2.5% | 16.6% | ||
| Q3 24 | 11.8% | 29.6% | ||
| Q2 24 | 1.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 0.7% | 5.1% | ||
| Q4 24 | 0.4% | 1.1% | ||
| Q3 24 | 0.6% | 2.4% | ||
| Q2 24 | 1.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACVA
| Auction Marketplace Revenue | $77.6M | 42% |
| Other Marketplace Revenue | $72.4M | 39% |
| Customer Assurance | $24.1M | 13% |
| Data Services Revenue | $9.4M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
